SCHEMBL2804024

SCHEMBL2804024

Cc1ccccc1-c1ccc(-c2nc(-c3ccc(C(=O)O)cc3F)no2)cc1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.67
S1PR1 P21453 11/20 0.61
S1PR3 Q99500 1/20 0.55
RARA P10276 1/20 0.52
RARB P10826 1/20 0.52
RARG P13631 1/20 0.52
NPC1 O15118 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 1/20 0.51
PKM P14618 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MAOA P21397 1/20 0.51
BLVRB P30043 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
RAB9A P51151 2/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2775433 0.88 S1PR1 (0.64) NR1H4S1PR1S1PR3NPC1SMN1; SMN2
SCHEMBL2774725 0.87 NR1H4 (0.74) NR1H4S1PR1S1PR3RARARARB
SCHEMBL2805606 0.87 S1PR1 (0.60) NR1H4S1PR1S1PR3RARARARB
SCHEMBL2773867 0.87 S1PR1 (0.76) NR1H4S1PR1S1PR3NPC1SMN1; SMN2
SCHEMBL2807738 0.84 S1PR1 (0.71) NR1H4S1PR1S1PR3RARARARB
SCHEMBL24212404 0.81 NR1H4 (1.00) NR1H4S1PR1RARARARBRARG
SCHEMBL14926437 0.79 S1PR1 (0.70) NR1H4S1PR1NPC1SMN1; SMN2MAPT
SCHEMBL2775227 0.79 MCL1 (0.61) NR1H4S1PR1S1PR3RARARARB
SCHEMBL13873720 0.78 S1PR1 (0.69) NR1H4S1PR1NPC1SMN1; SMN2MAPT
SCHEMBL2772848 0.78 S1PR1 (0.69) NR1H4S1PR1S1PR3RARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 NR1H4 1784/4885S1PR1 483/4885S1PR3 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.